Loading
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis / Respiratory Viral Infections Research / Pneumonia and Respiratory Infections · Journal article
Journal of Monno Medical College · August 11, 2026
A consensus or society position rather than new primary data.
This is a narrative review characterizing hMPV as an established respiratory pathogen affecting all age groups, with greatest burden in infants, older adults, and immunocompromised individuals. The review confirms diagnostic advances (RT-PCR) and clinical recognition but underscores the absence of licensed vaccines or specific antivirals, with supportive care remaining the standard approach. It identifies co-infections and gaps in understanding immunopathogenesis as priorities for future research and therapeutic development.
Narrative review. All age groups, with emphasis on infants, older adults, and immunocompromised individuals.
hMPV discovered in 2001 and now recognized as a leading cause of upper and lower respiratory tract infections across all age groups Greatest disease burden observed in infants, older adults, and immunocompromised individuals No licensed vaccine or specific antiviral therapy currently available; supportive care remains mainstay of management
Specific epidemiological figures, prevalence, or mortality rates not provided
Clinicians should recognize hMPV as a common respiratory pathogen across populations; diagnosis relies on nucleic acid testing; no specific antiviral or preventive options exist, limiting management to supportive care. Awareness of co-infection risk is warranted in vulnerable groups.
A comprehensive narrative review synthesizing current knowledge of hMPV epidemiology, clinical features, and management gaps; informs clinicians on disease recognition and the absence of specific therapies.
As stated by the source record.
Clinicians should recognize hMPV as a common respiratory pathogen across populations; diagnosis relies on nucleic acid testing; no specific antiviral or preventive options exist, limiting management to supportive care. Awareness of co-infection risk is warranted in vulnerable groups.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Human metapneumovirus (hMPV) has emerged as a significant pathogen responsible for a wide spectrum of respiratory illnesses across all age groups, with the greatest burden observed in infants, older adults, and immunocompromised individuals. Since its discovery in 2001, extensive research has revealed its epidemiology, clinical manifestations, modes of transmission, and impact on public health. It is now recognized as a leading cause of both upper and lower respiratory tract infections. Despite significant advances in diagnostic technologies—particularly nucleic acid amplification methods such as RT-PCR—and a growing understanding of the virology and immune response, no licensed vaccine or specific antiviral therapy is currently available. Supportive care remains the mainstay of management. Co-infections with hMPV and other respiratory pathogens, such as RSV or SARS-CoV, present additional challenges and may complicate disease severity. Moreover, the limited understanding of hMPV immunopathogenesis, particularly in vulnerable populations, emphasizes the necessity for further research. In conclusion, hMPV represents an important target for future therapeutic and preventive interventions. With ongoing research and development, especially in vaccine design and antiviral therapy, there is hope for reducing the global disease burden of hMPV and improving outcomes for those most at risk. Journal of Monno Medical College December, 2025;11(2):141-149
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.